Twitter Facebook LinkedIn WhatsApp Press Releases Any 2023 2022 2021 2020 2019 (-) 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 Reset 2018 December 2, 2018 argenx enters exclusive global collaboration and license agreement with Cilag GmbH International, an affiliate of Janssen, for cusatuzumab (ARGX-110) December 2, 2018 argenx Provides Detailed Data from Phase 2 Clinical Trial of Efgartigimod in Immune Thrombocytopenia and Phase 1/2 Clinical Trial of Cusatuzumab in Acute Myeloid Leukemia November 6, 2018 argenx to Present at Upcoming Investor Conferences October 31, 2018 argenx announces new cusatuzumab (ARGX-110) AML data in abstracts published in connection with 60th American Society of Hematology Annual Meeting and Exposition October 24, 2018 argenx reports third quarter 2018 financial results and provides business update October 8, 2018 argenx awarded €2.6 million VLAIO grant to explore new applications of ABDEG technology September 20, 2018 argenx announces closing of U.S. public offering September 18, 2018 argenx raises approximately $300.6 million in gross proceeds in a U.S. public offering September 16, 2018 argenx announces launch of proposed public offering in the United States September 16, 2018 argenx reports positive topline results from Phase 2 proof-of-concept trial of efgartigimod in primary immune thrombocytopenia September 5, 2018 argenx doses first patient in global Phase 3 registration trial of efgartigimod August 28, 2018 argenx receives feedback from Japan’s PMDA on Phase 3 clinical trial and regulatory pathway for efgartigimod in generalized myasthenia gravis Pagination Current page 1 Page 2 Page 3 Page 4 Next page Next › Last page Last »
